Lei Changhai, et al; and Hu Shi*; Neutralization of SARS CoV-2 spike pseudotyped virus by 2 recombinant ACE2-Ig, Nature Communications 11, 2070 (2020)

Fu, Wenyan; et al; and Hu, Shi*; CAR exosomes derived from effector CAR-T cells have potent antitumour effects and low toxicity. Nature Communications, 2019, 10: 0-4355.

Fu Wenyan, et a; and Hu, Shi*; EGFR/Notch Antagonists Enhance the Response to Inhibitors of the PI3K-Akt Pathway by Decreasing Tumor-Initiating Cell Frequency, Clinical Cancer Research, 2019, 25(9): 2835-2847.

Liu, Shuowu, et al, and Hu, Shi*; Treatment of murine lupus with TIGIT-Ig. Clinical immunology 203 (2019): 72-80.

Li, Tian, et al, and Hu, Shi*; Targeting RyR2 with a phosphorylation site–specific nanobody reverses dysfunction of failing cardiomyocytes in rats. The FASEB Journal 33.6 (2019): 7467-7478

Tian Li, et al, and Shi Hu*; Cardiac adenovirus-associated viral Presenilin 1 gene delivery protects the left ventricular function of the heart via regulating RyR2 function in post-ischemic heart failure. Journal of Drug Targeting 03/2018.

Shi Hu*, et al; Antagonism of EGFR and Notch limits resistance to EGFR inhibitors and radiation by decreasing tumor-initiating cell frequency. Science Translational Medicine 03/2017; 9(380).

Shi Hu*, et al; Broad RTK-targeted therapy overcomes molecular heterogeneity-driven resistance to cetuximab via vectored immunoprophylaxis in colorectal cancer. Cancer letters 08/2016; 382(1).

Shi Hu*, et al; Four-in-one antibodies have superior cancer inhibitory activity against EGFR, HER2, HER3, and VEGF through disruption of HER/MET crosstalk. Cancer Research 11/2014; 75(1).